Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
The trial will be conducted across eight sites in Maharashtra
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
The company has to approach the DCGI for approval to commence the trials
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Subscribe To Our Newsletter & Stay Updated
